TAVR-Fueled Growth and 2026 Guidance Might Change The Case For Investing In Edwards Lifesciences (EW)

Simply Wall St.02-20

In February 2026, Edwards Lifesciences reported fourth-quarter 2025 sales of US$1,569.6 million alongside a sharp drop in quarterly net income, while issuing first-quarter 2026 sales guidance of US$...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2612758258?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/411220-main-header/1756234467355","is_english":true,"pubTime":"2026-02-20 06:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612758258","market":"nz","top_or_hot":-1,"title":"TAVR-Fueled Growth and 2026 Guidance Might Change The Case For Investing In Edwards Lifesciences (EW)","media":"Simply Wall St.","content":"<div>\n<p>In February 2026, Edwards Lifesciences reported fourth-quarter 2025 sales of US$1,569.6 million alongside a sharp drop in quarterly net income, while issuing first-quarter 2026 sales guidance of US$...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-ew/edwards-lifesciences/news/tavr-fueled-growth-and-2026-guidance-might-change-the-case-f\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TAVR-Fueled Growth and 2026 Guidance Might Change The Case For Investing In Edwards Lifesciences (EW)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTAVR-Fueled Growth and 2026 Guidance Might Change The Case For Investing In Edwards Lifesciences (EW)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-20 06:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-ew/edwards-lifesciences/news/tavr-fueled-growth-and-2026-guidance-might-change-the-case-f><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In February 2026, Edwards Lifesciences reported fourth-quarter 2025 sales of US$1,569.6 million alongside a sharp drop in quarterly net income, while issuing first-quarter 2026 sales guidance of US$...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-ew/edwards-lifesciences/news/tavr-fueled-growth-and-2026-guidance-might-change-the-case-f\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0345774391.USD","symbol_name":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-ew/edwards-lifesciences/news/tavr-fueled-growth-and-2026-guidance-might-change-the-case-f","article_id":"2612758258","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/411220-main-header/1756234467355"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-ew/edwards-lifesciences/news/tavr-fueled-growth-and-2026-guidance-might-change-the-case-f","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2612758258","pubTimestamp":1771540395,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In February 2026, Edwards Lifesciences reported fourth-quarter 2025 sales of US$1,569.6 million alongside a sharp drop in quarterly net income, while issuing first-quarter 2026 sales guidance of US$1.55 billion to US$1.63 billion and full-year 2026 sales growth guidance of 8% to 10% with EPS of US$2.90 to US$3.05.\nA key highlight was the robust year-over-year growth in transcatheter aortic valve replacement (TAVR) sales, which now account for roughly three-quarters of Edwards’ revenue and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0345774391.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) ACC","BK4567":"ESG概念","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","BK4588":"碎股","IE00BYQQ9H92.USD":"BNY MELLON GLOBAL LEADERS \"A\" (USD) ACC","LU0345774631.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) INC","BK4585":"ETF&股票定投概念","BK4082":"医疗保健设备","EW":"爱德华兹","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SG9999001176.USD":"United Global Healthcare Acc USD","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","IE00BFXG0V08.USD":"BNY MELLON GLOBAL LEADERS \"B\" (USD) ACC","BK4504":"桥水持仓","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC"},"translate_title":"TAVR推动的增长和2026年指导可能会改变投资Edwards Lifesciences(EW)的理由","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EW":1.5},"content_text":"In February 2026, Edwards Lifesciences reported fourth-quarter 2025 sales of US$1,569.6 million alongside a sharp drop in quarterly net income, while issuing first-quarter 2026 sales guidance of US$1.55 billion to US$1.63 billion and full-year 2026 sales growth guidance of 8% to 10% with EPS of US$2.90 to US$3.05. A key highlight was the robust year-over-year growth in transcatheter aortic valve replacement (TAVR) sales, which now account for roughly three-quarters of Edwards’ revenue and underpin management’s confidence in its 2026 outlook. Now we’ll examine how strong TAVR sales momentum and reaffirmed 2026 guidance may influence Edwards Lifesciences’ broader investment narrative. AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.AdvertisementEdwards Lifesciences Investment Narrative RecapTo own Edwards Lifesciences, you need to believe its leadership in transcatheter heart therapies, especially TAVR, can translate solid procedure growth into consistent earnings despite cost and pricing pressures. The latest results show strong TAVR-driven sales but a sharp drop in net income, so the key near term catalyst is whether management can convert this top line momentum into margin stability. The biggest current risk remains execution on costs and tariffs rather than this specific quarter, which does not appear to change that materially. The reaffirmed 2026 guidance for 8% to 10% sales growth and EPS of US$2.90 to US$3.05 stands out against the weak recent earnings comparison. It directly ties the current TAVR performance to management’s confidence in meeting near term financial targets, while also implicitly testing their ability to manage tariff headwinds and higher operating expenses. How well Edwards tracks against this guidance will likely frame investor reactions to any future product or regulatory milestones. Yet against this constructive guidance, investors should still be aware that rising tariffs and operating costs could... Read the full narrative on Edwards Lifesciences (it's free!)Edwards Lifesciences' narrative projects $7.6 billion revenue and $1.8 billion earnings by 2028. This requires 10.0% yearly revenue growth and roughly a $0.4 billion earnings increase from $1.4 billion today.Uncover how Edwards Lifesciences' forecasts yield a $97.11 fair value, a 23% upside to its current price.Exploring Other PerspectivesEW 1-Year Stock Price Chart Three members of the Simply Wall St Community value Edwards Lifesciences between US$70.82 and US$97.11, highlighting how far opinions can diverge. When you set these views against management’s 2026 sales and EPS guidance, it becomes even more important to compare different expectations for how effectively Edwards can turn strong TAVR revenue into sustainable earnings.Explore 3 other fair value estimates on Edwards Lifesciences - why the stock might be worth as much as 23% more than the current price!The Verdict Is YoursDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Edwards Lifesciences research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.Our free Edwards Lifesciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Edwards Lifesciences' overall financial health at a glance.Curious About Other Options?The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Edwards Lifesciences might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2612758258","isCrawlerRequest":true}